Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumabcan mediate an immunologic tumor regression in other histologies. This phase II trial evaluated the efficacy of Ipilimumabfor advanced pancreatic cancer. Subjects were adults with locally advanced or metastatic pan